FDA Grants Accelerated Approval for Regeneron’s Otarmeni, Ushering in First Gene Therapy for Genetic Hearing Loss
TARRYTOWN, NEW YORK – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced a monumental stride in genetic medicine, with the U.S. Food and...
